FR3083090A1 - EMBOLIZATION OFFICER - Google Patents

EMBOLIZATION OFFICER Download PDF

Info

Publication number
FR3083090A1
FR3083090A1 FR1870788A FR1870788A FR3083090A1 FR 3083090 A1 FR3083090 A1 FR 3083090A1 FR 1870788 A FR1870788 A FR 1870788A FR 1870788 A FR1870788 A FR 1870788A FR 3083090 A1 FR3083090 A1 FR 3083090A1
Authority
FR
France
Prior art keywords
embolization
agent
biocompatible
radiopaque
mixture
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
FR1870788A
Other languages
French (fr)
Other versions
FR3083090B1 (en
Inventor
Rene Chapot
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to FR1870788A priority Critical patent/FR3083090B1/en
Priority to PCT/FR2019/000106 priority patent/WO2020008118A1/en
Publication of FR3083090A1 publication Critical patent/FR3083090A1/en
Application granted granted Critical
Publication of FR3083090B1 publication Critical patent/FR3083090B1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/14—Macromolecular materials
    • A61L27/16—Macromolecular materials obtained by reactions only involving carbon-to-carbon unsaturated bonds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/04—X-ray contrast preparations
    • A61K49/0409—Physical forms of mixtures of two different X-ray contrast-enhancing agents, containing at least one X-ray contrast-enhancing agent which is not a halogenated organic compound
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/04—X-ray contrast preparations
    • A61K49/0433—X-ray contrast preparations containing an organic halogenated X-ray contrast-enhancing agent
    • A61K49/0447—Physical forms of mixtures of two different X-ray contrast-enhancing agents, containing at least one X-ray contrast-enhancing agent which is a halogenated organic compound
    • A61K49/0461—Dispersions, colloids, emulsions or suspensions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L24/00—Surgical adhesives or cements; Adhesives for colostomy devices
    • A61L24/001—Use of materials characterised by their function or physical properties
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L24/00—Surgical adhesives or cements; Adhesives for colostomy devices
    • A61L24/0047—Composite materials, i.e. containing one material dispersed in a matrix of the same or different material
    • A61L24/0073—Composite materials, i.e. containing one material dispersed in a matrix of the same or different material with a macromolecular matrix
    • A61L24/0089—Composite materials, i.e. containing one material dispersed in a matrix of the same or different material with a macromolecular matrix containing inorganic fillers not covered by groups A61L24/0078 or A61L24/0084
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L24/00—Surgical adhesives or cements; Adhesives for colostomy devices
    • A61L24/04—Surgical adhesives or cements; Adhesives for colostomy devices containing macromolecular materials
    • A61L24/06—Surgical adhesives or cements; Adhesives for colostomy devices containing macromolecular materials obtained by reactions only involving carbon-to-carbon unsaturated bonds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/40—Composite materials, i.e. containing one material dispersed in a matrix of the same or different material
    • A61L27/42—Composite materials, i.e. containing one material dispersed in a matrix of the same or different material having an inorganic matrix
    • A61L27/427—Composite materials, i.e. containing one material dispersed in a matrix of the same or different material having an inorganic matrix of other specific inorganic materials not covered by A61L27/422 or A61L27/425
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2400/00—Materials characterised by their function or physical properties
    • A61L2400/04—Materials for stopping bleeding
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2400/00—Materials characterised by their function or physical properties
    • A61L2400/06—Flowable or injectable implant compositions

Abstract

La présente invention concerne les agents d'embolisation vasculaire. L'agent d'embolisation selon l'invention se caractérise essentiellement par le fait qu'il est constitué d'un mélange comportant un polymère biocompatible dissout dans un solvant biocompatible , et deux radio-opacifiants : une poudre radio-opaque et un agent radio-opaque soluble dans ledit solvant biocompatible. Application : réalisation d'injections au moyen d'un cathéter dans un vaisseau sanguin afin de provoquer mécaniquement et/ou biologiquement une occlusion temporaire ou durable de ce vaisseau sanguin.The present invention relates to vascular embolization agents. The embolization agent according to the invention is essentially characterized in that it consists of a mixture comprising a biocompatible polymer dissolved in a biocompatible solvent, and two radio-opacifiers: a radio-opaque powder and a radio agent opaque soluble in said biocompatible solvent. Application: performing injections by means of a catheter into a blood vessel in order to mechanically and / or biologically cause a temporary or lasting occlusion of this blood vessel.

Description

DescriptionDescription

Titre de l’invention : Agent d’embolisationTitle of invention: Embolization agent

Domaine technique [0001] La présente invention concerne les agents d’embolisation vasculaire.Technical Field [0001] The present invention relates to vascular embolization agents.

[0002] Les agents d'embolisation vasculaire se présentent sous différentes formes, solide, liquide, en suspension, etc. Ils sont injectés au moyen d’un cathéter dans un vaisseau sanguin afin de provoquer mécaniquement et/ou biologiquement une occlusion temporaire ou durable de ce vaisseau sanguin.[0002] Vascular embolization agents come in different forms, solid, liquid, in suspension, etc. They are injected through a catheter into a blood vessel in order to mechanically and / or biologically cause a temporary or lasting occlusion of this blood vessel.

[0003] Il est connu au moins deux types d'agents d'embolisation vasculaire se présentant sous la forme de particules, constituant les agents d'embolisation les plus utilisés (particules non sphériques, microsphères), ou de liquides (colles, gels, agents sclérosants, émulsions visqueuses).It is known at least two types of vascular embolization agents in the form of particles, constituting the most used embolization agents (non-spherical particles, microspheres), or liquids (adhesives, gels, sclerosing agents, viscous emulsions).

[0004] Il existe également de nouveaux agents que sont les microsphères chargeables en produits anticancéreux et les microsphères résorbables. L'appréciation de leur intérêt clinique repose sur une bonne évaluation de leur comportement mécanique dans les systèmes vasculaires, de leur comportement biologique comme implants et de leurs performances pharmacologiques comme systèmes de délivrance de médicaments.There are also new agents which are the microspheres which can be loaded with anticancer products and the absorbable microspheres. The appreciation of their clinical interest is based on a good evaluation of their mechanical behavior in vascular systems, their biological behavior as implants and their pharmacological performance as drug delivery systems.

[0005] C’est ainsi qu’il a été mis au point et utilisé un liquide d’embolisation composé d’éthylène vynil alcool (EVOH) dissout dans un solvant qui est essentiellement du dyméthyl sulfoxide (DMSO). Afin de rendre ce mélange radio-opaque, il a été ajouté un agent de contraste liquide comme le métrizamide. L’inconvénient de cet agent de contraste liquide est constitué par le fait qu’il augmente considérablement la viscosité du mélange.This is how it was developed and used an embolization liquid composed of ethylene vinyl alcohol (EVOH) dissolved in a solvent which is essentially dymethyl sulfoxide (DMSO). In order to make this mixture radiopaque, a liquid contrast agent such as metrizamide has been added. The disadvantage of this liquid contrast agent is that it considerably increases the viscosity of the mixture.

[0006] Pour contrer cet inconvénient, l’agent de contraste liquide a été remplacé par une poudre radio-opaque. L’intérêt de cette solution est que l’ajout de poudre ne modifie pas la viscosité du mélange EVOH-DMSO, ce qui a permis à l’agent embolique de garder une viscosité relativement faible et de conquérir le marché des emboles liquides pour le traitement des MAV (Malformations Arterio-Veineuses).To overcome this drawback, the liquid contrast agent was replaced by a radiopaque powder. The advantage of this solution is that the addition of powder does not modify the viscosity of the EVOH-DMSO mixture, which has allowed the embolic agent to keep a relatively low viscosity and to conquer the market of liquid emboli for treatment. MAV (Arterio-Venous Malformations).

[0007] Depuis plusieurs années, les Praticiens neuroradiologues réclament un agent d’embolisation vasculaire dont la radio-opacité disparaîtrait avec le temps. En effet, si le caractère radio-opaque de cet agent d’embolisation est indispensable pour le contrôle de son injection, il devient un inconvénient lorsqu’il faut « reprendre le malade », c’est-à-dire réaliser un complément d’embolisation lors d’une nouvelle intervention. Une MAV se traite en effet en plusieurs sessions, par l’embolisation progressive des multiples vaisseaux sanguins afférents. L’analyse et le contrôle d’une embolisation effectuée à la suite d’embolisations précédentes se trouvent gênés par la masse de liquide embolique précédemment injecté dont la radio-opacité masque les vaisseaux qui s’y superposent. Ceci est un avantage majeur pour les médecins utilisateurs car l’embolisation non contrôlée d’une MAV peut conduire à la rupture d’un vaisseau sanguin et au décès du patient.For several years, neuroradiologist practitioners have been asking for a vascular embolization agent, the radio-opacity of which would disappear over time. Indeed, if the radiopaque character of this embolization agent is essential for the control of its injection, it becomes a disadvantage when it is necessary to "take back the patient", that is to say to carry out an additional embolization during a new intervention. An AVM is treated in several sessions, by the progressive embolization of the multiple afferent blood vessels. The analysis and control of an embolization carried out following previous embolizations are hampered by the mass of embolic fluid previously injected whose radiopacity masks the vessels which are superimposed on it. This is a major advantage for user physicians since uncontrolled embolization of an AVM can lead to rupture of a blood vessel and death of the patient.

[0008] Pour tenter de répondre à cette demande, des recherches sur l’utilisation d’un agent radio-opacifiant ont été effectuées au moyen d’un produit qui est en substance de l’acide iothalamique, qui disparaîtrait avec le temps. Mais ces recherches ont été abandonnées, certainement confrontées au problème de l’augmentation trop importante de la viscosité provoquée par l’ajout d’acide iothalamique nécessaire en trop grande quantité.In an attempt to meet this demand, research on the use of a radio-opacifying agent has been carried out using a product which is essentially iothalamic acid, which would disappear over time. But this research was abandoned, certainly faced with the problem of the excessive increase in viscosity caused by the addition of too much iothalamic acid required.

Buts de l'invention [0009] La présente invention a pour but de réaliser un agent d’embolisation vasculaire qui pallie les inconvénients des agents d’embolisation de l’art antérieur et qui réponde aux buts définis ci-dessus.AIMS OF THE INVENTION The aim of the present invention is to provide a vascular embolization agent which overcomes the drawbacks of the embolization agents of the prior art and which meets the aims defined above.

Définition de l’invention [0010] Plus précisément, la présente invention a pour objet la réalisation d’un agent d’embolisation vasculaire constitué d’un mélange comportant un polymère biocompatible dissout dans un solvant biocompatible, et deux radio-opacifiants : une poudre radio-opaque et un agent radio-opaque soluble dans ledit solvant biocompatible.Definition of the invention More specifically, the present invention relates to the production of a vascular embolization agent consisting of a mixture comprising a biocompatible polymer dissolved in a biocompatible solvent, and two radio-opacifiers: a powder radiopaque and a radiopaque agent soluble in said biocompatible solvent.

[0011] Selon une autre caractéristique de l’invention, l’agent d’embolisation comporte au moins l’un des éléments suivants pris isolément ou en combinaison avec au moins un autre de ces éléments :According to another characteristic of the invention, the embolization agent comprises at least one of the following elements taken individually or in combination with at least one other of these elements:

• élément (i) : ledit polymère biocompatible est constitué par de l’éthylène vynil alcool (EVOH), • élément (ii) : ledit solvant biocompatible est du dyméthyl sulfoxide (DMSO), • élément (iii) : ledit agent radio-opaque est un agent à base d’iode soluble dans le solvant (ii), et • élément (iv) : ladite poudre radio-opaque est choisie parmi les matériaux suivants : Tantale, Tungstène, Or, Platine, Carbonate de Bismuth, une combinaison d’au moins deux ces matériaux.• element (i): said biocompatible polymer consists of ethylene vinyl alcohol (EVOH), • element (ii): said biocompatible solvent is dymethyl sulfoxide (DMSO), • element (iii): said radiopaque agent is an agent based on iodine soluble in the solvent (ii), and • element (iv): said radiopaque powder is chosen from the following materials: Tantalum, Tungsten, Gold, Platinum, Bismuth Carbonate, a combination of 'at least two of these materials.

[0012] Selon une autre caractéristique de l’invention, les proportions des composants du mélange, données en pourcentage (%) de poids, sont sensiblement comprises entre 2% et 40% pour le EVOH ; sensiblement comprises entre 40% et 60% pour le DMSO ; sensiblement comprises entre 2% et 57 % pour la poudre radio-opaque ; sensiblement comprises entre 1% et 47% pour l’agent radio-opaque soluble dans le solvant.According to another characteristic of the invention, the proportions of the components of the mixture, given as a percentage (%) by weight, are substantially between 2% and 40% for the EVOH; substantially between 40% and 60% for DMSO; substantially between 2% and 57% for the radiopaque powder; substantially between 1% and 47% for the solvent-soluble radiopaque agent.

[0013] D'autres caractéristiques et avantages de la présente invention apparaîtront au cours de la description suivante donnée à titre illustratif, mais nullement limitatif.Other features and advantages of the present invention will become apparent from the following description given by way of illustration, but in no way limiting.

Brève description d’un mode de mise en œuvre de l’invention [0014] La présente invention concerne un agent d’embolisation vasculaire constitué d’un mélange comportant un polymère biocompatible dissout dans un solvant biocompatible, et deux radio-opacifiants : une poudre radio-opaque et un agent radioopaque soluble dans le solvant biocompatible.Brief description of an embodiment of the invention The present invention relates to a vascular embolization agent consisting of a mixture comprising a biocompatible polymer dissolved in a biocompatible solvent, and two radio-opacifiers: a powder radio-opaque and a radio-opaque agent soluble in the biocompatible solvent.

[0015] Ce mélange permet de conférer à l’agent d’embolisation une bonne fluidité, le rendant donc plus facile à injecter dans les vaisseaux sanguins, et une durée de radioopacité maximale relativement plus courte que celle des agents d’embolisation de l’art antérieur, ce qui permet à son opacité d’être moins gênante que celle que peuvent avoir les agents de l’art antérieur, permettant ainsi de répondre à la demande des Praticiens comme évoqué au préambule de la présente description.This mixture makes it possible to give the embolization agent good fluidity, therefore making it easier to inject into the blood vessels, and a relatively shorter maximum radioopacity duration than that of the embolization agents. prior art, which allows its opacity to be less annoying than that which agents of the prior art may have, thus making it possible to meet the demand of Practitioners as mentioned in the preamble to this description.

[0016] Selon une caractéristique de la présente invention particulièrement préférentielle, l’agent d’embolisation comporte au moins l’un des éléments suivants pris isolément ou en combinaison avec au moins un autre de ces éléments :According to a particularly preferred characteristic of the present invention, the embolization agent comprises at least one of the following elements taken individually or in combination with at least one other of these elements:

[0017] · élément (i) : le polymère biocompatible est constitué par de l’éthylène vynil alcool (EVOH), [0018] · élément (ii) : le solvant biocompatible est du dyméthyl sulfoxide (DMSO), [0019] · élément (iii) : l’agent radio-opaque est un agent à base d’iode soluble dans le solvant biocompatible, [0020] · élément (iv) : la poudre radio-opaque est choisie dans les matériaux suivants :Element (i): the biocompatible polymer consists of ethylene vinyl alcohol (EVOH), element (ii): the biocompatible solvent is dymethyl sulfoxide (DMSO), element (iii): the radio-opaque agent is an iodine-based agent soluble in the biocompatible solvent, element (iv): the radio-opaque powder is chosen from the following materials:

Tantale, Tungstène, Or, Platine, Carbonate de Bismuth, une combinaison d’au moins deux ces matériaux.Tantalum, Tungsten, Gold, Platinum, Bismuth Carbonate, a combination of at least two of these materials.

[0021] Selon une autre caractéristique, elle aussi préférentielle, de la présente invention, l’agent à base d’iode mentionné ci-dessus est de l’acide iothalamique.According to another characteristic, also preferred, of the present invention, the iodine-based agent mentioned above is iothalamic acid.

[0022] Selon une autre caractéristique de la présente invention, le mélange est réalisé de façon que sa viscosité soit sensiblement comprise entre 4 et 600 centipoises.According to another characteristic of the present invention, the mixture is produced so that its viscosity is substantially between 4 and 600 centipoise.

[0023] Selon une autre caractéristique de la présente invention, les dimensions des grains composant la poudre sont comprises entre environ 0,00003 mm (0,03 microns) et environ 0,010 mm (10 microns).According to another characteristic of the present invention, the dimensions of the grains making up the powder are between approximately 0.00003 mm (0.03 microns) and approximately 0.010 mm (10 microns).

[0024] Selon une autre caractéristique de la présente invention, les proportions des composants du mélange, données en pourcentage (%) de poids, sont sensiblement comprises entre 2% et 40% pour l’élément (i) ; sensiblement comprises entre 40% et 60% pour l’élément (ii) ; sensiblement comprises entre 2% et 57 % pour l’élément (iii) ; sensiblement comprises entre 1% et 47% pour l’élément (iv).According to another characteristic of the present invention, the proportions of the components of the mixture, given as a percentage (%) by weight, are substantially between 2% and 40% for the element (i); significantly between 40% and 60% for element (ii); significantly between 2% and 57% for element (iii); substantially between 1% and 47% for element (iv).

[0025] Les résultats obtenus lors d’essais cliniques effectués avec l’agent d’embolisation vasculaire tel que défini ci-dessus, sont très prometteurs, à la satisfaction des Praticiens.The results obtained in clinical trials carried out with the vascular embolization agent as defined above, are very promising, to the satisfaction of practitioners.

Claims (1)

Revendications claims [Revendication 1] [Claim 1] Agent d’embolisation vasculaire, caractérisé par le fait qu’il est constitué d’un mélange comportant un polymère biocompatible dissout dans un solvant biocompatible, et deux radio-opacifiants : une poudre radio-opaque et un agent radio-opaque soluble dans ledit solvant biocompatible. Vascular embolization agent, characterized in that it consists of a mixture comprising a biocompatible polymer dissolved in a biocompatible solvent, and two radiopacifiers: a radiopaque powder and a radiopaque agent soluble in said solvent biocompatible. [Revendication 2] [Claim 2] Agent d’embolisation selon la revendication 1, caractérisé par le fait qu’il comporte au moins l’un des éléments suivants pris isolément ou en combinaison avec au moins un autre de ces éléments : • élément (i) : ledit polymère biocompatible est constitué par de l’éthylène vynil alcool (EVOH), • élément (ii) : ledit solvant biocompatible est du dyméthyl sulfoxide (DMSO), • élément (iii) : ledit agent radio-opaque est un agent à base d’iode soluble dans le solvant biocompatible, • élément (iv) : ladite poudre radio-opaque est choisie parmi les matériaux suivants : Tantale, Tungstène, Or, Platine, Carbonate de Bismuth, une combinaison d’au moins deux de ces matériaux. Embolization agent according to claim 1, characterized in that it comprises at least one of the following elements taken alone or in combination with at least one other of these elements: Element (i): said biocompatible polymer consists of ethylene vinyl alcohol (EVOH), Element (ii): said biocompatible solvent is dymethyl sulfoxide (DMSO), Element (iii): said radiopaque agent is an iodine-based agent soluble in the biocompatible solvent, • element (iv): said radiopaque powder is chosen from the following materials: Tantalum, Tungsten, Gold, Platinum, Bismuth Carbonate, a combination of at least two of these materials. [Revendication 3] [Claim 3] Agent d’embolisation selon la revendication 2, caractérisé par le fait que ledit agent à base d’iode est de l’acide iothalamique. Embolization agent according to Claim 2, characterized in that the said iodine-based agent is iothalamic acid. [Revendication 4] [Claim 4] Agent d’embolisation selon l’une des revendications précédentes, caractérisé par le fait ledit mélange est réalisé de façon que sa viscosité soit sensiblement comprise entre 4 et 600 centipoises. Embolization agent according to one of the preceding claims, characterized in that the said mixture is produced so that its viscosity is substantially between 4 and 600 centipoise. [Revendication 5] [Claim 5] Agent d’embolisation selon l’une des revendications précédentes, caractérisé par le fait que les dimensions des grains composant ladite poudre radio-opaque sont comprises entre environ 0,00003 mm (0,03 microns) et environ 0,10 mm (10 microns). Embolization agent according to one of the preceding claims, characterized in that the dimensions of the grains making up said radiopaque powder are between approximately 0.00003 mm (0.03 microns) and approximately 0.10 mm (10 microns ). [Revendication 6] [Claim 6] Agent d’embolisation selon l’une des revendications précédentes quand elle dépend de la revendication 2, caractérisé par le fait que les proportions des composants du mélange, données en pourcentage (%) de poids, sont sensiblement comprises entre 2% et 40% pour l’élément (i) ; sensiblement comprises entre 40% et 60% pour l’élément (ii) ; sensiblement comprises entre 2% et 57 % pour l’élément (iii) ; sensiblement comprises entre 1% et 47% pour l’élément (iv). Embolization agent according to one of the preceding claims when it depends on claim 2, characterized in that the proportions of the components of the mixture, given in percentage (%) by weight, are substantially between 2% and 40% for element (i); significantly between 40% and 60% for element (ii); significantly between 2% and 57% for element (iii); substantially between 1% and 47% for element (iv).
RÉPUBLIQUE FRANÇAISEFRENCH REPUBLIC
FR1870788A 2018-07-02 2018-07-02 EMBOLIZATION OFFICER Active FR3083090B1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
FR1870788A FR3083090B1 (en) 2018-07-02 2018-07-02 EMBOLIZATION OFFICER
PCT/FR2019/000106 WO2020008118A1 (en) 2018-07-02 2019-06-26 Embolisation agent

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR1870788A FR3083090B1 (en) 2018-07-02 2018-07-02 EMBOLIZATION OFFICER
FR1870788 2018-07-02

Publications (2)

Publication Number Publication Date
FR3083090A1 true FR3083090A1 (en) 2020-01-03
FR3083090B1 FR3083090B1 (en) 2020-06-05

Family

ID=65031565

Family Applications (1)

Application Number Title Priority Date Filing Date
FR1870788A Active FR3083090B1 (en) 2018-07-02 2018-07-02 EMBOLIZATION OFFICER

Country Status (2)

Country Link
FR (1) FR3083090B1 (en)
WO (1) WO2020008118A1 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113995884A (en) * 2021-09-10 2022-02-01 苏州浩微生物医疗科技有限公司 Liquid embolic agent and preparation method thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000071170A1 (en) * 1999-05-21 2000-11-30 Micro Therapeutics, Inc. Novel high viscosity embolizing compositions
US20020183764A1 (en) * 2000-10-10 2002-12-05 Kazushi Kinugasa Embolic materials
EP1625871A1 (en) * 1998-02-27 2006-02-15 Micro Therapeutics, Inc. Gynecological embolization

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1625871A1 (en) * 1998-02-27 2006-02-15 Micro Therapeutics, Inc. Gynecological embolization
WO2000071170A1 (en) * 1999-05-21 2000-11-30 Micro Therapeutics, Inc. Novel high viscosity embolizing compositions
US20020183764A1 (en) * 2000-10-10 2002-12-05 Kazushi Kinugasa Embolic materials

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113995884A (en) * 2021-09-10 2022-02-01 苏州浩微生物医疗科技有限公司 Liquid embolic agent and preparation method thereof

Also Published As

Publication number Publication date
WO2020008118A1 (en) 2020-01-09
FR3083090B1 (en) 2020-06-05

Similar Documents

Publication Publication Date Title
Zur et al. The role of steroids in the management of diabetic macular edema
EP2512389B1 (en) Intracameral devices for sustained delivery
Chiang et al. Sustained reduction of intraocular pressure by supraciliary delivery of brimonidine-loaded poly (lactic acid) microspheres for the treatment of glaucoma
KR101430760B1 (en) Ocular therapy using glucocorticoid derivatives selectively penetrating posterior segment tissues
US8642067B2 (en) Methods and compositions for intraocular administration to treat ocular conditions
AU2005271700B2 (en) Opthalmic compositions and methods for treating ophthalmic conditions
DE602005004022T2 (en) INTRA-OCCULAR STEROID IMPLANTS WITH DELAYED RELEASE FOR A PERIOD OF OVER 2 MONTHS
JP2008540552A (en) Ophthalmic treatment using alpha-2 adrenergic receptor agonists with increased anterior clearance rate
WO2010048086A1 (en) Drug delivery systems and methods for treating neovascularization
EP2411013A1 (en) Intraocular sustained release drug delivery systems and methods for treating ocular conditions
KR20070004927A (en) Anti-excitotoxic sustained release intraocular implants and related methods
TW200528114A (en) Compositions and methods for treating a posterior segment of an eye
FR3083090A1 (en) EMBOLIZATION OFFICER
CA2905327A1 (en) Compositions and their use to treat complications of aneurysmal subarachnoid hemorrhage
Zehtabi et al. Chitosan–sodium tetradecyl sulfate hydrogel: characterization and preclinical evaluation of a novel sclerosing embolizing agent for the treatment of endoleaks
US20230293764A1 (en) Embolic compositions and methods
EP2424497A2 (en) Intraocular bioactive agent delivery compositon including a molecular partitioning system
EP1581274B1 (en) Injectable gel-forming compositions based on cross-linked and non-cross-linked polymers and the use thereof
EP2353624A1 (en) Embolic material, its process of preparation and its therapeutical uses thereof
US20230001043A1 (en) Liquid embolic material composition
Seron et al. An embolic gelling solution based on acrylic copolymers in ethanol for the treatment of arteriovenous malformations
JP2022520182A (en) Vitreous substitutes that release antioxidants and their use
AU2013221985B2 (en) Ophthalmic compositions and methods for treating ophthalmic conditions
Tabi et al. Microprolactinome ou kyste de la poche de Rathke: un défi diagnostique
Reed et al. Calcium Gluconatee Mediated In-Situ Gelling of Alginates for Ocular Drug Delivery

Legal Events

Date Code Title Description
PLFP Fee payment

Year of fee payment: 2

PLSC Publication of the preliminary search report

Effective date: 20200103

PLFP Fee payment

Year of fee payment: 3

PLFP Fee payment

Year of fee payment: 4

PLFP Fee payment

Year of fee payment: 5

PLFP Fee payment

Year of fee payment: 6